Literature DB >> 34219948

Worsening of renal function and uncontrolled hypertension from intravitreal bevacizumab injections.

Moeed Ahmed1, Neil Alouch2, Arslan Ahmed1, Sunil K Jagadesh3.   

Abstract

Vascular endothelial growth factor (VEGF) inhibitors are used in the treatment of various cancers as well as diabetic retinopathy. The systemic use of these drugs has been associated with adverse effects such as worsening hypertension, proteinuria, and renal function. There have been some reported cases of worsening hypertension, thrombotic microangiopathy, or glomerular disease after intravitreal injections of bevacizumab, aflibercept, and ranibizumab. We present a case of a patient who was taking intravitreal bevacizumab injections for diabetic retinopathy and was hospitalized with worsening renal function, high blood pressure, and nephrotic-range proteinuria in the setting of tight glycemic control.
Copyright © 2021 Baylor University Medical Center.

Entities:  

Keywords:  Diabetic nephropathy; hypertension; intravitreal bevacizumab

Year:  2021        PMID: 34219948      PMCID: PMC8224191          DOI: 10.1080/08998280.2021.1885285

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  8 in total

1.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Authors:  I M Stratton; A I Adler; H A Neil; D R Matthews; S E Manley; C A Cull; D Hadden; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

2.  The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension.

Authors:  R Rasier; O Artunay; E Yuzbasioglu; A Sengul; H Bahcecioglu
Journal:  Eye (Lond)       Date:  2008-12-12       Impact factor: 3.775

3.  VEGF inhibition and renal thrombotic microangiopathy.

Authors:  Vera Eremina; J Ashley Jefferson; Jolanta Kowalewska; Howard Hochster; Mark Haas; Joseph Weisstuch; Catherine Richardson; Jeffrey B Kopp; M Golam Kabir; Peter H Backx; Hans-Peter Gerber; Napoleone Ferrara; Laura Barisoni; Charles E Alpers; Susan E Quaggin
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

4.  Minimal change disease onset observed after bevacizumab administration.

Authors:  Ramy M Hanna; Eduardo Lopez; James Wilson; Shrinath Barathan; Arthur H Cohen
Journal:  Clin Kidney J       Date:  2015-12-28

5.  Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center.

Authors:  Hassan Izzedine; Bernard Escudier; Catherine Lhomme; Patricia Pautier; Philippe Rouvier; Victor Gueutin; Alain Baumelou; Lisa Derosa; Rastilav Bahleda; Antoine Hollebecque; Djillali Sahali; Jean Charles Soria
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

6.  SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.

Authors:  Robert L Avery; Alessandro A Castellarin; Nathan C Steinle; Dilsher S Dhoot; Dante J Pieramici; Robert See; Stephen Couvillion; Maʼan A Nasir; Melvin D Rabena; Mauricio Maia; Sherri Van Everen; Kha Le; William D Hanley
Journal:  Retina       Date:  2017-10       Impact factor: 4.256

7.  Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension.

Authors:  Ramy M Hanna; Eduardo A Lopez; Huma Hasnain; Umut Selamet; James Wilson; Peter N Youssef; Nermeen Akladeous; Suphamai Bunnapradist; Michael B Gorin
Journal:  Clin Kidney J       Date:  2018-07-27

8.  Bevacizumab-induced immunoglobulin A vasculitis with nephritis: A case report.

Authors:  Yoko Endo; Kousuke Negishi; Kento Hirayama; Hitoshi Suzuki; Akira Shimizu
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

  8 in total
  1 in total

Review 1.  Pro- and anti-fibrotic effects of vascular endothelial growth factor in chronic kidney diseases.

Authors:  Changxiu Miao; Xiaoyu Zhu; Xuejiao Wei; Mengtuan Long; Lili Jiang; Chenhao Li; Die Jin; Yujun Du
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.